Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sole Challenger HEC Beaten On US Gilenya Patent

Key Patent to December 2027 Upheld

Executive Summary

Imminent generic competition to Novartis’ Gilenya blockbuster in the US now seems impossible after a US district court held that the company’s dosage-regimen patent was both valid and infringed by HEC’s ANDA product. The Chinese firm may yet appeal the decision.

You may also be interested in...



$10bn Sandoz Business May Be Sold Or Spun As Novartis Weighs Options

Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.

Argentum Falters Again On Gilenya As US Supreme Court Says No

The US Supreme Court has denied Argentum Pharmaceuticals’ petition for certiorari review of an unfavorable Federal Circuit decision that considered whether the generics player had the standing to appeal a PTAB ruling.

Tentative Xeljanz XR Approval Among Several For Zydus Cadila

Zydus Cadila has clocked up two tentative and four final abbreviated new drug application approvals in a short amount of time, including for Boehringer Ingelheim’s Jentadueto and the discontinued verapamil hydrochloride for injection.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel